To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL

NCT05651191 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Acute Lymphoblastic Leukemia

Interventions

DRUG: Human CD19 Targeted DASH CAR-T Cells Injection

Sponsor

Hrain Biotechnology Co., Ltd.

Collaborators

[object Object]